The efficacy of desipramine in reducing methamphetamine craving

Phase 2

• Conditions: Metamphetamine use disorder.; Other stimulant dependence, uncomplicated; F15.20

• Registration Number: IRCT20160813029315N2
• Lead Sponsor: Mental Health Research Center

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 26 August 2019

Recruitment & Eligibility

• Status: Complete
• Sex: Male
• Target Recruitment: 40

Inclusion Criteria

Age between 18 to 50
Current diagnosis of methamphetamine use disorder based on DSM IV-TR criteria
Positive urine test for methamphetamine prior to study entry
Male gender

Exclusion Criteria

Having conditions known to be deteriorated following desipramine use such as obesity, liver diseases, and cardiovascular diseases
Taking antidepressants of any class in during the two weeks prior to entering the study
Taking medications with potential effect on methamphetamine craving (i.e. modafinil, bupropion, naltrexone, N-acetylcysteine)
Taking medications known to adversely interact with desipramine
Serious mood disorders, suicidal ideation, and psychotic disorders requiring hospitalization
Comorbid medical conditions, as revealed by history review, physical exam, or laboratory results of blood chemistry test and liver profile
Incidence of a life-threatening side effect following medication use (i.e. liver failure, pancreatitis, hepatic encephalopathy, thrombocytopenia, leucopenia)
Medication intolerance
Use of other substances (except methadone maintenance therapy, nicotine, cannabis, and morphine) confirmed by a toxicology screen
Currently (during a month prior to study) in treatment for methamphetamine use
Having DSM IV-TR diagnosis of other substance use disorders in the past year
No longer willing to participate in the study

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Metamphemine craving. Timepoint: before intervention, at the end of each month after intervention until 4 months (0-1-2-3-4). Method of measurement: Cocaine Craving Questionnaire-Brief.;Positive urine toxicology test for methamphetamine. Timepoint: Before intervention, at the end of each month after intervention until 4 months (0-1-2-3-4). Method of measurement: Urine toxicology test.

Secondary Outcome Measures

Name	Time	Method
Drug Side Effects. Timepoint: Before intervention and at the end of each month after intervention until 4 months (0-1-2-3-4). Method of measurement: Side effects questionnaire.